What guidance did the company provide for the full‑year 2025 outlook, including revenue, EBITDA, and cash flow?

Guidance Summary (as disclosed in the release):

STRATA Skin Sciences did not disclose explicit numeric targets for FY 2025 in the excerpt provided. The press release only states that the company “provides a corporate update” alongside its Q2 2025 results, but the specific figures for full‑year revenue, EBITDA, and cash‑flow outlook were not included in the summary excerpt. To obtain the exact guidance figures—e.g., projected revenue range, expected EBITDA margin, and cash‑flow expectations—you will need to review the complete press release or the company’s investor‑relations page where the full FY 2025 outlook is normally disclosed.

Trading Implications:

Because the actual FY 2025 guidance numbers are unavailable from the provided snippet, it is prudent to hold off on any position that relies solely on those metrics until the full data set is reviewed. In the meantime, focus on the broader market context: STRATA’s stock is currently reacting to its Q2 2025 earnings beat (if any) and the broader sentiment in the medical‑technology sector. If the full‑year guidance, once released, shows revenue and EBITDA upside relative to analyst consensus, the stock could experience a bullish catalyst; conversely, a down‑beat outlook could pressure the share price. As a short‑term trader, monitor the upcoming detailed filing (10‑Q or press release) for the exact guidance numbers, and watch for accompanying analyst commentary that could amplify price movement. Until the numbers are known, maintain a neutral stance or consider a small‑position hedge based on broader sector momentum rather than the specific FY 2025 outlook.